Patients with laboratory evidence of West Nile virus disease without reported fever.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 1 8 2019
pubmed: 1 8 2019
medline: 3 4 2020
Statut: ppublish

Résumé

In 2013, the national surveillance case definition for West Nile virus (WNV) disease was revised to remove fever as a criterion for neuroinvasive disease and require at most subjective fever for non-neuroinvasive disease. The aims of this project were to determine how often afebrile WNV disease occurs and assess differences among patients with and without fever. We included cases with laboratory evidence of WNV disease reported from four states in 2014. We compared demographics, clinical symptoms and laboratory evidence for patients with and without fever and stratified the analysis by neuroinvasive and non-neuroinvasive presentations. Among 956 included patients, 39 (4%) had no fever; this proportion was similar among patients with and without neuroinvasive disease symptoms. For neuroinvasive and non-neuroinvasive patients, there were no differences in age, sex, or laboratory evidence between febrile and afebrile patients, but hospitalisations were more common among patients with fever (P < 0.01). The only significant difference in symptoms was for ataxia, which was more common in neuroinvasive patients without fever (P = 0.04). Only 5% of non-neuroinvasive patients did not meet the WNV case definition due to lack of fever. The evidence presented here supports the changes made to the national case definition in 2013.

Identifiants

pubmed: 31364561
pii: S0950268819001079
doi: 10.1017/S0950268819001079
pmc: PMC6624872
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e219

Références

N Engl J Med. 2001 Jun 14;344(24):1807-14
pubmed: 11407341
Lancet. 2001 Jul 28;358(9278):261-4
pubmed: 11498211
Emerg Infect Dis. 2003 Mar;9(3):376-9
pubmed: 12643836
Emerg Infect Dis. 2003 Jul;9(7):788-93
pubmed: 12890318
Emerg Infect Dis. 2005 Aug;11(8):1174-9
pubmed: 16102303
Emerg Infect Dis. 2006 Jul;12(7):1129-31
pubmed: 16836833
Rev Med Virol. 2006 Jul-Aug;16(4):209-24
pubmed: 16906589
Emerg Infect Dis. 2007 Dec;13(12):1918-20
pubmed: 18258047
J Infect Dis. 2010 Nov 1;202(9):1354-61
pubmed: 20874087
JAMA. 2013 Jul 17;310(3):308-15
pubmed: 23860989
Diagn Microbiol Infect Dis. 2014 Feb;78(2):132-6
pubmed: 24316017
Viruses. 2014 Feb 06;6(2):606-23
pubmed: 24509812

Auteurs

K Landry (K)

Arboviral Diseases Branch,Centers for Disease Control and Prevention,Fort Collins, CO,USA.

I B Rabe (IB)

Arboviral Diseases Branch,Centers for Disease Control and Prevention,Fort Collins, CO,USA.

S L Messenger (SL)

Viral and Rickettsial Disease Laboratory,California Department of Public Health,Richmond, CA,USA.

J K Hacker (JK)

Viral and Rickettsial Disease Laboratory,California Department of Public Health,Richmond, CA,USA.

M L Salas (ML)

Viral and Rickettsial Disease Laboratory,California Department of Public Health,Richmond, CA,USA.

C Scott-Waldron (C)

Louisiana Office of Public Health,Baton Rouge, LA,USA.

D Haydel (D)

Louisiana Office of Public Health,Baton Rouge, LA,USA.

E Rider (E)

Louisiana Office of Public Health,Baton Rouge, LA,USA.

S Simonson (S)

Louisiana Office of Public Health,Baton Rouge, LA,USA.

C M Brown (CM)

Massachusetts Department of Public Health,Jamaica Plain, MA,USA.

S C Smole (SC)

Massachusetts Department of Public Health,Jamaica Plain, MA,USA.

D F Neitzel (DF)

Minnesota Department of Health,Saint Paul, MN,USA.

E K Schiffman (EK)

Minnesota Department of Health,Saint Paul, MN,USA.

A K Strain (AK)

Minnesota Department of Health,Saint Paul, MN,USA.

S Vetter (S)

Minnesota Department of Health,Saint Paul, MN,USA.

M Fischer (M)

Arboviral Diseases Branch,Centers for Disease Control and Prevention,Fort Collins, CO,USA.

N P Lindsey (NP)

Arboviral Diseases Branch,Centers for Disease Control and Prevention,Fort Collins, CO,USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH